Ana Maria Wägner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ana Maria Wägner has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Antonio Pérez
2 shared publicationsJordi Ordóñez-Llanos
Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona, Barcelona, Spain
2 shared publicationsAntonio Pérez
Endocrinology and Nutrition Department, Hospital de Sant Pau, Universitat Autònoma, Barcelona, Spain
1 shared publication- Cristina Bancells
Servei de Bioquímica, Institut de Recerca, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
1 shared publication Edgar Zapico
Endocrinology and Nutrition Department, Hospital de Sant Pau, Universitat Autònoma, Barcelona, Spain
1 shared publication- Jordi Ordóñez-Llanos
Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain
1 shared publication
Latest Publications
- 1 July 2011
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 93 (1) , e25-e28
Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study
- 1 July 2011
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 93 (1) , e25-e28
Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study
- 1 November 2004
- Published by Elsevier in Metabolism
- Vol. 53 (11) , 1516
Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes
- 1 November 2004
- Published by Elsevier in Metabolism
- Vol. 53 (11) , 1516
Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes
- 1 July 2003
- Published by American Diabetes Association in Diabetes Care
- Vol. 26 (7) , 2048-2051
Non-HDL Cholesterol and Apolipoprotein B in the Dyslipidemic Classification of Type 2 Diabetic Patients
OBJECTIVE—To compare non-HDL cholesterol (HDLc) and apolipoprotein B (apoB) in the identification of nonconventional high-risk dyslipidemic phenotypes in type 2 diabetic patients. RESEARCH DESIGN AND METHODS—Total cholesterol and triglycerides, HDLc, LDL cholesterol, non-HDLc, apolipoprotein B (apoB), and LDL size were determined in 122 type 2 diabetic patients (68% male, aged 59.6 ± 9.7 years, and HbA1c 7.5% [range 5.2–16.0]). They were then classified as normo- and hypertriglyceridemic if their triglyceride concentrations were below/above 2.25 mmol/l, as normo/hyper-non-HDLc if non-HDLc concentrations were below/above 4.13 mmol/l, and as normo- and hyperapoB if apoB concentrations were below/above 0.97 g/l. Both classifications were compared (concordance assessed with the κ index), and low HDLc and LDL phenotype B were identified in each category. RESULTS—A total of 26 patients were hypertriglyceridemic and 96 were normotriglyceridemic. All hypertriglyceridemic subjects had increased non-HDLc, whereas 24 had increased apoB (κ= 0.95). In the normotriglyceridemic group, 44 had increased non-HDLc, 68 had increased apoB, and 25 of the 52 patients with normal non-HDLc had increased apoB (κ= 0.587). Low HDLc and LDL phenotype B were similarly distributed into the equivalent categories. CONCLUSIONS—Non-HDLc and apoB are equivalent risk markers in hypertriglyceridemic patients, but apoB identifies additional patients with high-risk dyslipidemic phenotypes in normotriglyceridemic type 2 diabetic patients.
- 1 July 2003
- Published by American Diabetes Association in Diabetes Care
- Vol. 26 (7) , 2048-2051
Non-HDL Cholesterol and Apolipoprotein B in the Dyslipidemic Classification of Type 2 Diabetic Patients
OBJECTIVE—To compare non-HDL cholesterol (HDLc) and apolipoprotein B (apoB) in the identification of nonconventional high-risk dyslipidemic phenotypes in type 2 diabetic patients. RESEARCH DESIGN AND METHODS—Total cholesterol and triglycerides, HDLc, LDL cholesterol, non-HDLc, apolipoprotein B (apoB), and LDL size were determined in 122 type 2 diabetic patients (68% male, aged 59.6 ± 9.7 years, and HbA1c 7.5% [range 5.2–16.0]). They were then classified as normo- and hypertriglyceridemic if their triglyceride concentrations were below/above 2.25 mmol/l, as normo/hyper-non-HDLc if non-HDLc concentrations were below/above 4.13 mmol/l, and as normo- and hyperapoB if apoB concentrations were below/above 0.97 g/l. Both classifications were compared (concordance assessed with the κ index), and low HDLc and LDL phenotype B were identified in each category. RESULTS—A total of 26 patients were hypertriglyceridemic and 96 were normotriglyceridemic. All hypertriglyceridemic subjects had increased non-HDLc, whereas 24 had increased apoB (κ= 0.95). In the normotriglyceridemic group, 44 had increased non-HDLc, 68 had increased apoB, and 25 of the 52 patients with normal non-HDLc had increased apoB (κ= 0.587). Low HDLc and LDL phenotype B were similarly distributed into the equivalent categories. CONCLUSIONS—Non-HDLc and apoB are equivalent risk markers in hypertriglyceridemic patients, but apoB identifies additional patients with high-risk dyslipidemic phenotypes in normotriglyceridemic type 2 diabetic patients.